{
    "organizations": [],
    "uuid": "070475faaee482a5bdb33bfb51405363632a6e7c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-inflarx-announces-first-patient-en/brief-inflarx-announces-first-patient-enrolled-in-phase-iib-trial-with-lead-candidate-ifx-1-in-hidradenitis-suppurativa-idUSFWN1QQ0V0",
    "ord_in_thread": 0,
    "title": "BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8, 2018 / 2:47 PM / in 11 minutes BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa Reuters Staff 1 Min Read March 8 (Reuters) - Inflarx Nv: * INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA Source text for Eikon: Further company coverage:",
    "published": "2018-03-08T16:47:00.000+02:00",
    "crawled": "2018-03-08T17:04:25.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "minute",
        "announces",
        "first",
        "patient",
        "enrolled",
        "phase",
        "iib",
        "trial",
        "lead",
        "candidate",
        "hidradenitis",
        "suppurativa",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "inflarx",
        "nv",
        "inflarx",
        "announces",
        "first",
        "patient",
        "enrolled",
        "phase",
        "iib",
        "trial",
        "lead",
        "candidate",
        "hidradenitis",
        "suppurativa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}